Bristol Myers Squibb

News

BMS swoops on Mirati with $5.8bn takeover offer

After months of speculation about a possible takeover of Mirati Therapeutics, Bristol-Myers Squibb has reached a deal to buy the company and its KRAS inhibitor Krazati in

News

Anthos hails win over Xarelto with novel anticoagulant

Anthos Therapeutics says a phase 2b trial of its factor XI inhibitor anticoagulant abelacimab has been stopped early due to an “overwhelming” reduction in bleeding complic

News

First-in-class BMS drug raises lung fibrosis hopes

Bristol-Myers Squibb has proof-of-concept data for an experimental drug for fibrotic diseases that could open up a new avenue for treatment.

News

BMS grabs key approval for Reblozyl in MDS

Bristol-Myers Squibb's blockbuster aspirations for Reblozyl have been given a boost by the FDA after it approved the drug as a first-line treatment for anaemia in patients

News

AZ and BMS resolve checkpoint inhibitor patent disputes

AstraZeneca has said that a trio of lawsuits filed by Bristol-Myers Squibb and Ono Pharma alleging patent infringement with its checkpoint inhibitor drugs Imjudo and Imfin

News

BMS feels the pain of Revlimid erosion, cutting forecasts

Bristol-Myers Squibb is facing some serious near-term challenges as its top-selling drugs come under pressure, forcing it to slash its sales forecasts for the year.

BMS swoops on Mirati with $5.8bn takeover offer

Anthos hails win over Xarelto with novel anticoagulant

First-in-class BMS drug raises lung fibrosis hopes

BMS grabs key approval for Reblozyl in MDS

AZ and BMS resolve checkpoint inhibitor patent disputes

BMS feels the pain of Revlimid erosion, cutting forecasts

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Bristol Myers Squibb

Editor's Picks